Age-Related Macular Degeneration Market Report 2025

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.96 billion in 2024 to $10.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population demographics, changing lifestyles and environmental factors, genetic predisposition, increased awareness and early diagnosis, advancements in diagnostic techniques.

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $14.38 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to research in genetics and biomarkers, emerging therapeutic modalities, telemedicine and remote monitoring, patient advocacy and education. Major trends in the forecast period include personalized medicine approaches, innovations in retinal imaging technologies, emergence of sustained drug delivery systems, clinical trials for investigational therapies, collaborations for research and development.

The anticipated growth in the age-related macular degeneration (AMD) market is expected to be driven by the increasing prevalence of AMD, a progressive eye condition that affects the macula, a crucial part of the retina responsible for central vision. Treatments for age-related macular degeneration aim to mitigate the severity of the disease, and the rising prevalence of AMD is a significant factor contributing to market growth. According to reports from Optimaxa, a UK-based laser eye treatment specialist, as of February 2023, approximately 196 million individuals worldwide are affected by age-related macular degeneration (AMD), with projections estimating a rise to 288 million by 2040. This would account for 8.7 percent of the global population. The escalating prevalence of AMD underscores the need for effective treatments and is a key driver for the growth of the age-related macular degeneration market.

The expanding aging population is anticipated to boost the growth of the age-related macular degeneration (AMD) market in the coming years. The term "aging population" describes a demographic shift characterized by an increasing proportion or number of individuals aged 65 years and older within a society. As the global elderly population rises, there is also a corresponding increase in the prevalence of AMD, a progressive eye condition that affects central vision. For example, in January 2024, the Population Reference Bureau, a U.S.-based nonprofit organization, projected that the number of Americans aged 65 and older will increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. Additionally, the share of this age group in the total population is expected to grow from 17% to 23% during the same period. Consequently, the increasing aging population is a key factor driving the growth of the age-related macular degeneration market.

Leading companies in the age-related macular degeneration (AMD) market are focusing on developing innovative treatments, such as bispecific antibodies, to reduce the frequency of treatments. A bispecific antibody is an engineered antibody that can bind to two different antigens at the same time. For example, in May 2022, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Vabysmo intravitreal injection 120 mg/mL, a bispecific antibody aimed at treating eye conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). This innovative therapy works by simultaneously targeting two critical pathways: angiopoietin-2 (Ang-2), which plays a role in abnormal blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), a key factor in the formation of new blood vessels that can result in vision loss. A significant advantage of Vabysmo is its extended dosing intervals, allowing treatments to be given every 16 weeks, thereby improving patient convenience and adherence. Its dual-action mechanism represents a major advancement in ophthalmic treatments, effectively meeting the urgent need for dependable therapies in retinal diseases.

Key players in the age-related macular degeneration (AMD) market are advancing innovative technologies, such as recombinant antigen-binding fragments. These recombinant antigen-binding fragments (Fab) are engineered proteins derived from antibodies that specifically target and bind to certain antigens, and are often used therapeutically to inhibit disease-related pathways. For example, in December 2023, Enzene Biosciences, a biotechnology company based in India, launched ranibizumab, a recombinant monoclonal antibody fragment (Fab) specifically designed to inhibit vascular endothelial growth factor (VEGF), a critical protein involved in the formation of abnormal blood vessels in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). By blocking VEGF, ranibizumab effectively reduces the leakage and proliferation of these blood vessels, helping to preserve vision in patients suffering from these retinal disorders. Administered through intravitreal injection, ranibizumab has become widely accepted in clinical practice due to its effectiveness in treating various retinal diseases. Its introduction has significantly improved the treatment landscape for patients dealing with these serious conditions.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to expand its presence in the ophthalmology market and accelerate the development of novel treatments for age-related macular degeneration. IVERIC Bio Inc., a US-based biotech corporation, specializes in the development of drugs and products for treating age-related macular degeneration, making it a strategic addition to Astellas Pharma's portfolio in the ophthalmology sector.

Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

North America was the largest region in the global age-related macular degeneration market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Age-related macular degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, located at the center of the retina, resulting in a gradual loss of central vision due to aging. Therapeutic options for AMD encompass regular eye examinations, lifestyle modifications, and specific nutritional supplements.

There are two main types of age-related macular degeneration, wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD). Wet AMD is a progressive eye disease marked by the growth of abnormal blood vessels beneath the macula, the central part of the retina responsible for sharp, central vision. Treatment for wet AMD involves the use of various drugs such as Eylea, Lucentis, Avastin, and others. These drugs are administered through intravenous and intravitreal routes and are typically dispensed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The age-related macular degeneration market research report is one of a series of new reports that provides age-related macular degeneration market statistics, including age-related macular degeneration industry global market size, regional shares, competitors with an age-related macular degeneration market share, detailed age-related macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. This age-related macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.